Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Phase 1 Cancer Trials

Seattle, Washington

Phase 1 cancer trials in Seattle, WA

90 Phase 1 cancer studies are recruiting participants at sites in Seattle as of November 17, 2026, according to ClinicalTrials.gov. Phase 1 Cancer Trials can help you understand your options and connect with a study team.

Call (888) 927-9038
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Seattle at a glance

Breast cancer studies recruiting in Seattle

Basic details from each study's public record (the 30 most recently updated of 90). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. A Phase 1/2 Study of IAM1363 in HER2 Cancers

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Iambic Therapeutics, Inc
    Study site
    Fred Hutchinson Cancer Center
    Registry record
    NCT06253871 · updated
  2. Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Boehringer Ingelheim
    Study site
    Fred Hutchinson Cancer Research Center
    Registry record
    NCT06324357 · updated
  3. A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Astellas Pharma Global Development, Inc.
    Study site
    Virginia Mason Medical Center
    Registry record
    NCT07488676 · updated
  4. Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.

    • Phase 1/2
    • All ages
    • All sexes
    Sponsor
    RayzeBio, Inc.
    Registry record
    NCT06590857 · updated
  5. An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    BeOne Medicines
    Study site
    Fred Hutchinson Cancer Research Center
    Registry record
    NCT07222267 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Seattle, WA on ClinicalTrials.gov.

Lung cancer studies recruiting in Seattle

  1. Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Institut de Recherches Internationales Servier
    Study site
    Fred Hutchinson Cancer Research Center
    Registry record
    NCT05786924 · updated
  2. A Study of VET3-TGI in Patients With Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    KaliVir Immunotherapeutics
    Study site
    University of Washington, Fred Hutchinson Cancer Center
    Registry record
    NCT06444815 · updated
  3. A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    IDEAYA Biosciences
    Study site
    Swedish Cancer Institute
    Registry record
    NCT07277413 · updated
  4. Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Boehringer Ingelheim
    Study site
    Fred Hutchinson Cancer Research Center
    Registry record
    NCT04886804 · updated
  5. Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    SystImmune Inc.
    Study site
    University of Washington/Fred Hutchinson Cancer Center
    Registry record
    NCT07080242 · updated
  6. A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Verastem, Inc.
    Study site
    Virginia Mason Medical Center
    Registry record
    NCT07020221 · updated
  7. A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    BlossomHill Therapeutics
    Study site
    Fred Hutchinson Cancer Center
    Registry record
    NCT06706076 · updated
  8. T Cell Receptor T Cells for Advanced KRAS G12V-mutant Non-small Cell Lung Cancer, Pancreas Cancer, Colon Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Fred Hutchinson Cancer Center
    Study site
    Fred Hutch/University of Washington Cancer Consortium
    Registry record
    NCT06043713 · updated
  9. A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Novartis Pharmaceuticals
    Study site
    Fred Hutchinson Cancer Center
    Registry record
    NCT07564401 · updated
  10. AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

    • Phase 1/2
    • Ages 18 to 75
    • All sexes
    Sponsor
    Avenzo Therapeutics, Inc.
    Study site
    Avenzo Therapeutics Recruiting Site
    Registry record
    NCT07038343 · updated
  11. A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Moonlight Bio, Inc
    Study site
    Fred Hutch Cancer Center
    Registry record
    NCT07488923 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Seattle, WA on ClinicalTrials.gov.

Prostate cancer studies recruiting in Seattle

  1. Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer

    • Phase 1
    • Ages 18 and older
    • Male participants
    Sponsor
    Astellas Pharma Global Development, Inc.
    Study site
    Fred Hutchinson Cancer Research Center
    Registry record
    NCT05997615 · updated
  2. Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

    • Phase 1
    • Ages 18 and older
    • Male participants
    Sponsor
    Amgen
    Study site
    Fred Hutchinson Cancer Center
    Registry record
    NCT04221542 · updated
  3. A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer

    • Phase 1
    • Ages 18 and older
    • Male participants
    Sponsor
    Janssen Research & Development, LLC
    Study site
    Swedish Medical Center
    Registry record
    NCT06095089 · updated
  4. A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer

    • Phase 1
    • Ages 18 and older
    • Male participants
    Sponsor
    Janssen Research & Development, LLC
    Study site
    Fred Hutchinson Cancer Center
    Registry record
    NCT07082920 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Seattle, WA on ClinicalTrials.gov.

Lymphoma studies recruiting in Seattle

  1. The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

    • Phase 1/2
    • Up to age 22
    • All sexes
    Sponsor
    PedAL BCU, LLC
    Study site
    Seattle Children's Hospital
    Registry record
    NCT04726241 · updated
  2. A Study of Zedoresertib (Debio 0123) in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Zedoresertib (Debio 0123) in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Debiopharm International SA
    Study site
    Fred Hutchinson Cancer Research Center
    Registry record
    NCT05765812 · updated
  3. A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

    • Phase 1
    • Ages 0 to 18
    • All sexes
    Sponsor
    Autolus Limited
    Study site
    Seattle Children's Hospital
    Registry record
    NCT06173518 · updated
  4. BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    PeproMene Bio, Inc.
    Study site
    Providence Swedish Cancer Institute
    Registry record
    NCT05370430 · updated
  5. A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

    • Phase 1/2
    • Ages 12 and older
    • All sexes
    Sponsor
    Nuvalent Inc.
    Study site
    Fred Hutchinson Cancer Center
    Registry record
    NCT05384626 · updated
  6. A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    Swedish Cancer Institute (SCI)
    Registry record
    NCT07101328 · updated
  7. A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    University of Washington - Fred Hutchinson Cancer Center (Seattle Cancer Care Alliance)
    Registry record
    NCT07226843 · updated
  8. A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    BeOne Medicines
    Study site
    Fred Hutchinson Cancer Research Center
    Registry record
    NCT06697184 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Seattle, WA on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in Seattle

  1. Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    University of Washington
    Study site
    Fred Hutch/University of Washington Cancer Consortium
    Registry record
    NCT07645651 · updated
  2. A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Artios Pharma Ltd
    Study site
    Fred Hutchinson Cancer Center / University of Washington
    Registry record
    NCT04657068 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Seattle, WA on ClinicalTrials.gov.

Ask about studies near Seattle

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 1, including early Phase 1 and combined Phase 1/2, as each study is coded in the registry.

Phase 1 Cancer Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 927-9038

or send a short form

How should we reach you?

Call